Aquila Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aquila Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,000	Closed	-$448K	–	65
2024 Q1	$448K	Hold	3,000	–	–	0.38%	63
2023 Q4	$574K	Buy	3,000 +1,000	+50%	+$170K	0.5%	72
2023 Q3	$354K	Hold	2,000	–	–	0.33%	81
2023 Q2	$380K	Hold	2,000	–	–	0.31%	86
2023 Q1	$401K	Hold	2,000	–	–	0.33%	82
2022 Q4	$475K	Hold	2,000	–	–	0.37%	85
2022 Q3	$400K	Buy	+2,000	New	+$381K	0.3%	88

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aquila Investment Management's ALNY Position: Q2 2024 in Review

Aquila Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 3,000 shares — an estimated $448K sold.

Aquila Investment Management first reported a position in ALNY in Q3 2022 and held it in 7 quarters. The position peaked at $574K in Q4 2023. 522 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

Aquila Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Aquila Investment Management sold 3,000 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $448K.
Aquila Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 7 quarters.
Aquila Investment Management's Alnylam Pharmaceuticals position peaked at $574K in Q4 2023.
522 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Aquila Investment Management's 13F filing for Q2 2024, filed 24 Jul 2024.